Live Breaking News & Updates on Pharma stocks

Stay informed with the latest breaking news from Pharma stocks on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Pharma stocks and stay connected to the pulse of your community

smallcaps: April will be a consolidation period for midcaps and smallcaps: Vishal Malkan

Vishal Malkan expects midcaps and smallcaps to consolidate in April. Nifty to remain range-bound. Dr Lal PathLabs surges, correction awaited for entry. Weakness in Nifty IT index continues. Malkan says: "I like the main part of PSUs like the PSU banks which are my favourites. Canara Bank and PNB are my top two stocks for this year."

Lucknow , Uttar-pradesh , India , Kozhikode , Kerala , Canara , Karnataka , Lal-pathlabs , Vishal-malkan , Vishal-malkanof-malkansview , Canara-bank , Offering-college

pharma stocks in news: Will the wave of restructuring help? 7 MNC pharma stocks with upside potential of up to 14%

In the last three years, Novartis is the third MNC pharma company which has announced sale of a part of its business in India. Some of these restructuring are being done as part of the global readjustment being made at the parent companies level. The bigger question is whether after this restructuring will the MNC pharma stocks, which have been underperforming for quite some time, be able to make a comeback on the street or not. This answer to this question would depend on multiple factors. Right from the use of the sale proceeds to whether post restructuring focus would be on a 100 percent subsidiary or not. In both positive and negative cases, these stocks probably should be on watchlist as news flow around them increases in coming quarters. We take a look at 7 MNC pharma companies.

India , Market-research , Google , Novartis , Unlimited-access , Economic-times , Saver-sale , Membershipclaim-offer , Prime-story , Debit-cards , Includes-docubay

granules india: Stock Radar: Up 50% in 6 months! Why Granules India could keep hitting record highs: Ajit Mishra

The pharma stock rose from Rs 291 on August 14 to Rs 435 recorded on February 15, which translates into an upside of about 50% in six months. It rose more than 6% in a week and over 20% in the last 3 months. The momentum helped the stock to break out from a month-long consolidation.

India , Granules-india , Stock-radar , Pharma-stocks , Granules-india-shares , Granules-india-share-price , Ajit-mishra ,

Business and valuation tailwinds to help in outperformance? 5 Indian pharma stocks with upside potential of up to 32%

Just before the whole market was consumed by the PSU rally, one sector that came into the limelight after many years of underperformance was the Indian pharma companies, yes they are very different in every sense from MNC pharma. During the PSU rally, these pharma stocks have been consolidating, however, in the last few days, some of them have once again started reacting to positive developments in the individual company indicating that there is money on the sideline that is ready to come into these stocks. Sectors like pharma which have seen a very long phase of business remodelling and valuation readjustment need to be brought back on the watch list. It might be too early to call, but if a re-rating gets momentum once again then they might be better candidates for volatile markets.

Market-research , Google , Unlimited-access , Economic-times , Saver-sale , Membershipclaim-offer , Prime-story , Debit-cards , Includes-docubay , Economic-times-stories , Industry-trends

value themes: Time to shed historical baggage in market; 4 spaces to look for value: N Jayakumar

N Jayakumar highlights the need to view the market differently due to the influx of younger, retail, aggressive investors. He suggests finding comfort in private sector banks, pharma stocks, OMCs, and power sectors. The market should shed historical baggage and focus on future potential. He said: "You need to learn from the past but you cannot ignore the present and therein lies the truth."

India , China , Lucknow , Uttar-pradesh , Aurobindo-pharma , Sun-pharma , Indian-school-of-business , Offering-college , Prime-securities , Coal-india , Leadership-excellence , Executive-officer

Choice Broking's Sumeet Bagadia lists Cipla as top 'Valentine's Day 2024 Pick'; here's why

Sumeet Bagadia of Choice Broking has chosen Cipla as his ‘Valentine's Day 2024 Pick’. Bagadia has recommended a ‘Buy’ on the pharma stock at ₹1,450 and up to ₹1,415 for a target price of ₹1,600 to ₹1,660.

United-states , India , South-africa , America , Umang-vohra , Motilal-oswal , Cipla , Exponential-moving-averages , Relative-strength-index , Choice-broking , View-full-image , Nifty-pharma

pharma stocks: Pramod Amthe is selective in midcaps; betting on 4 pharma stocks

The better way to play pharma is Sun Pharma and Aurobindo which we like. The other trend is domestic outlook for the growth for pharma. The proxy there is Torrent and Ajanta.Railways have new avenues of growth and strong momentum. Medium-term targets and government support improve growth prospects. Larger railway stocks like Concor, Kalpataru, and KEC are attractive due to their involvement in electrification lines. Having said that, some of the mid and smallcaps have run up much sharper.

Lucknow , Uttar-pradesh , India , Ajanta , Maharashtra , Kozhikode , Kerala , Bharat , Sun-pharma , Pramod-amthe , Cipla , Offering-college

Defensive bet with macro tailwinds? 5 Indian pharma stocks with upside potential of up to 20%

On Tuesday, when the whole market was reeling under pressure, two stocks reacted to their numbers in a positive direction. Both of them were large caps from one sector which is pharma. This becomes significant from three perspectives. First, that positive reaction was there on the day when there was a bloodbath on the street. Second, these stocks were already sitting on gains, so there is little probability of short covering leading to this sort of gains. Last but not the least it has come from sectors like pharma which have seen a very long phase of business remodelling and valuation readjustment, which makes it worth noticing. It might be too early to call, but if a re-rating gets momentum then they might be candidates for volatile markets.

Google , Market-research , Unlimited-access , Economic-times , Saver-sale , Membershipclaim-offer , Prime-story , Debit-cards , Includes-docubay , Economic-times-stories , Industry-trends

stock pick: Mileen Vasudeo on 2 pharma stocks to be on now

Mileen Vasudeo says: “Nifty is likely to head towards 22,300 to 22,500 levels. But yes, at lower levels like say 21,900, there is good support. Overall, the breadth of the market remains positive throughout the trading session. On the sector front, IT has really lifted the sentiments and the pharma pack is also looking good on the charts.”

Lucknow , Uttar-pradesh , India , Kozhikode , Kerala , Mileen-vasudeo , Vikas-nigam , Indian-school-of-business , Offering-college , Eicher-motors , Bajaj-auto , Senior-technical-research-analyst

Stock Radar: New 52-week high in Jan! Breakout from inverse Head & Shoulder pattern makes Divi's Labs an attractive buy

Short-term traders can look to buy the stock on decline up to Rs 4,000 levels, a crucial support and also closer to the neckline area of the inverse Head and shoulder pattern. An Inverse Head and shoulder pattern is the mirror image of the Head and Shoulder pattern and is a bullish signal.

Stock-radar , Pharma-stocks , Divi-rsquos-share-price , Divi-rsquos-labs-share-price , Divi-rsquos-labs , Divis-shares , Divis-laboratories ,